{"id":"W4294941528","doi":"10.1016/j.jtho.2022.07.781","title":"EP08.02-098 Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Platinum; Internal medicine; First line; Phase (matter); Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001283902,0.001347155,0.00184538,0.0004371218,0.0003689568,0.001479553,0.001135801,0.001388823,0.006255124],"category_scores_gemma":[0.000600867,0.0005533429,0.001260024,0.0002894994,0.0006673711,0.0006832464,0.0004183093,0.003563349,0.002088933],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001108742,"about_ca_system_score_gemma":0.001696399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00219848,"about_ca_topic_score_gemma":0.005438788,"domain_scores_codex":[0.9996972,0.000118653,0.00001060619,0.00003986742,0.00003904772,0.00009457245],"domain_scores_gemma":[0.9996312,0.00004669483,0.0000382328,0.0000308028,0.00003076378,0.0002223547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4450513,0.1099413,0.007574443,0.001523167,0.002351839,0.0006803799,0.0005114547,0.01128284,0.1382585,0.001713523,0.02623121,0.2548799],"study_design_scores_gemma":[0.464776,0.4806228,0.01521749,0.00008642788,0.0008581486,0.000740461,0.0001765675,0.004185965,0.01431254,0.0005461118,0.01841624,0.00006134046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841016,0.001962464,0.0007194339,0.0008539391,0.0003242569,0.002261528,0.003298881,0.0002561988,0.006221688],"genre_scores_gemma":[0.9632249,0.002573406,0.002298685,0.002055339,0.0002401236,0.002860337,0.00928589,0.0001437688,0.01731747],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006255124,"threshold_uncertainty_score":0.02092546,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05716515662775516,"score_gpt":0.4736893181085445,"score_spread":0.4165241614807893,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}